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Abstract
Interleukin (IL)-21 is an attractive antitumor agent with potent immunomodulatory functions. Yet thus far, the cytokine
has yielded only partial responses in solid cancer patients, and conditions for beneficial IL-21 immunotherapy remain
elusive. The current work aims to identify clinically-relevant IL-21 regimens with enhanced efficacy, based on
mathematical modeling of long-term antitumor responses. For this purpose, pharmacokinetic (PK) and pharmacodynamic
(PD) data were acquired from a preclinical study applying systemic IL-21 therapy in murine solid cancers. We developed
an integrated disease/PK/PD model for the IL-21 anticancer response, and calibrated it using selected ‘‘training’’ data. The
accuracy of the model was verified retrospectively under diverse IL-21 treatment settings, by comparing its predictions to
independent ‘‘validation’’ data in melanoma and renal cell carcinoma-challenged mice (R
2.0.90). Simulations of the
verified model surfaced important therapeutic insights: (1) Fractionating the standard daily regimen (50 mg/dose) into a
twice daily schedule (25 mg/dose) is advantageous, yielding a significantly lower tumor mass (45% decrease); (2) A low-
dose (12 mg/day) regimen exerts a response similar to that obtained under the 50 mg/day treatment, suggestive of an
equally efficacious dose with potentially reduced toxicity. Subsequent experiments in melanoma-bearing mice
corroborated both of these predictions with high precision (R
2.0.89), thus validating the model also prospectively in
vivo. Thus, the confirmed PK/PD model rationalizes IL-21 therapy, and pinpoints improved clinically-feasible treatment
schedules. Our analysis demonstrates the value of employing mathematical modeling and in silico-guided design of solid
tumor immunotherapy in the clinic.
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Introduction
Cancer is a multi-faceted disease, involving complex interac-
tions between neoplastic cells and the surrounding microenviron-
ment [1]. The prospect of immunotherapy, i.e. stimulating
endogenous immune responses by various molecular and cellular
factors, is emerging as a promising approach against this disease
[1,2,3]. One of the latest candidates for solid cancer immuno-
therapy is Interleukin (IL)-21, a cc-signaling protein of the IL-2
cytokine family with versatile immune-modulating properties
[4,5,6,7,8]. IL-21 has demonstrated substantial antitumor respons-
es in several independent preclinical studies, in which mice
inoculated with diverse transplantable syngeneic tumor lines were
treated with the drug via cytokine-gene transfection, plasmid
delivery, or injection of the recombinant protein [9]. In Phase I
and IIa clinical trials, IL-21 was well tolerated and triggered
moderate antitumor activity in some renal cell carcinoma (RCC)
and metastatic melanoma (MM) patients [10,11,12,13,14]. More
recently, clinical trials of IL-21 in combination with the tyrosine
kinase inhibitor sorafinib for the treatment of RCC, and
Rituximab for the treatment of non-Hodgkin’s lymphoma, have
also been investigated with encouraging results [15].
Yet, the intricate biology of IL-21 may set hurdles for its clinical
development. Produced mainly by activated CD4+ T cells, IL-21
induces anticancer immunity predominantly by stimulation of
natural killer cells (NKs) and/or cytotoxic T lymphocytes (CTLs)
[4,5,6,7]. The cytokine regulates various cellular and humoral
pathways of immunity, and exerts conflicting stimulatory and
inhibitory effects on several cell types [9,16,17]. Recent evidence for
anti-angiogenic effects of IL-21 [18] further complicates its
dynamical influence on the tumor microenvironment. Considering
this biological complexity, traditional ‘‘trial-and-error’’ methodolo-
gies for clinical IL-21 therapy design are likely inefficient, and ought
to be replaced by new guided approaches to maximize drug efficacy.
Rational and systematic planning of anticancer therapy may be
directed by mathematical modeling and computer-aided analysis,
which provides a better understanding of the involved dynamics.
Over the past 25 years, mathematical modeling strategies have
been applied in oncology-focused studies investigating tumor
progression, angiogenesis and interactions with the immune
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cytokine-based direct and supportive cancer drugs have been
introduced, with some being subsequently validated in preclinical
and clinical settings [23,25,26,27,28,29,30,31,32,33,34,35,36].
These strategies have highlighted the importance of adequate
selection of therapeutic regimens to achieve desired outcomes, by
carrying out in-depth analysis of optimal times, dosages, and
durations of treatment. Pharmacokinetic (PK) and pharmacody-
namic (PD) modeling of anticancer agents can be particularly
useful for clinical design of treatment [37,38].
We have previously developed a mathematical model for the
local dynamic effects of IL-21 on solid cancers. The model focused
on interactions of IL-21 with NKs/CTLs, effector cytotoxicity
against target cells, and immune memory, providing initial
understanding of the optimal conditions for IL-21 gene therapy
[39,40].
Here, we have designed a new comprehensive PK/PD/disease
model to predict clinically relevant scenarios of IL-21 treatment
following intravenous (IV) subcutaneous (SC) or intraperitoneal
(IP) administration in different cancer indications. The model
forecasts long-term effects of the drug by integrating newly
described PK/PD processes together with a disease model, based
on our initial in situ model [39,40]. This new combined model was
retrospectively and prospectively validated by in vivo experiments
in IL-21-treated mice bearing melanoma (B16) or renal cell
carcinoma (RenCa). Model predictions provide substantial insights
concerning adequate planning of systemic IL-21 therapy in solid
cancers.
Materials and Methods
Ethics statement
All experiments were conducted according to Novo Nordisk
principles for animal studies, as approved by the Danish National
Ethics Committee on Experimental Animals, and in accordance
with National Institute of Health guidelines for the care and use of
laboratory animals.
Experimental data
Data were collected from a published preclinical study in which
mice bearing B16 and RenCa tumors were treated with IL-21 by
various strategies [41]. Briefly, tumors were induced at day 0, and
a daily (B16) or 36/week (RenCa) IL-21 regimen (50 mg/dose)
was applied SC or IP either at an ‘‘early’’ stage (day 3 in B16; day
7 in RenCa), or at a ‘‘late’’ stage (day 8 in B16; day 12 in RenCa)
of tumor development. The tumor was measured several times
until experiment termination. Data were available from additional
unpublished dose-titration experiments in RenCa: IL-21 was given
SC, 16or 36/week, and groups of mice (n=6) were assigned a
dose between 1-50 mg. The complete database was a priori divided
into ‘‘training datasets’’ for model parameter estimation, and
‘‘validation datasets’’ for model verification.
In new prospective experiments designed to test model-
suggested regimens, 7-8-week-old wild type C57BL/6 mice
(Taconic Europe A/S, Denmark) were inoculated SC in the right
flank with 1610
5 B16F0 melanoma cells (American Type Culture
Collection (ATCC), CRL-6322) on day 0. Recombinant murine
IL-21 (Novo Nordisk A/S, Denmark) or PBS was injected SC
from day 3, when tumors were visible. IL-21 was given at 12 mg/
day, 50 mg/day, or 25 mg twice a day, each group including n=10
mice. Tumor volumes were calculated by the formula
volume~0:5|d2
1|d2,if d1v d2,based on the two perpendicular
diameters d1 and d2 measured approximately 36/week with digital
callipers. All experiments were carried out blindly, without the
investigator’s knowledge of model predictions. Animals were
randomized and ear-tagged prior to treatment onset and
euthanized when individual tumor volumes reached 1000 mm
3.
Model structure
The new comprehensive systemic model for IL-21 immuno-
therapy contains PK/PD effects merged with disease interactions,
as schemed in Fig. 1. The system is described hereafter, and the
coupled ordinary differential equations (ODEs) are fully detailed in
the Text S1 (sections A-B).
PK model. To describe IL-21 PK following standard
administration routes, we used experimental profiles of IL-21
serum concentrations in mice after SC, IP, or IV application of a
single 50 mg dose [41]. Since the PK events induced under IL-21
treatment are not fully defined, a non-traditional PK modeling
strategy, involving generalized assumptions and a ‘‘multiple-
modeling’’ approach, was employed. According to this approach
severalalternative PKmodels,differinginnumberof compartments
andconnectivity,weredevelopedandtested,leadingtotheselection
of the best performing one. The constructed models were all semi-
physiological, incorporating standard PK processes (i.e. drug
transport, absorption, and excretion). Each alternative structure
was designed to support all three administration routes (SC, IP, and
IV), and thus generalized to consider processes mutual or exclusive
to the different administration routes. In addition, for every
considered model structure and administration route, we
calibrated not a single parameter set, but rather ten alternative
sets that were tested for satisfying the PK model and fitting the data
(for the detailed calibration process, see Parameter estimation). This
approach, akin to similar multi-modeling strategies exercised in past
comparable models [42,43,44], is thought to enhance the validity of
the model: the predicted outcomes would not depend on one
parameter set, and therefore would be more robust, and less
sensitive to fluctuations [42].
The multiple-modeling approach identified a minimal, eight-
compartment model, which effectively recreated the experimental
IL-21 PK profiles under all three administration routes (Fig. 1, see
Text S1, section A, for detailed equations and structure of the
Author Summary
Among the many potential drugs explored within the
scope of cancer immunotherapy are selected cytokines
which possess promising immune-boosting properties.
Yet, the natural involvement of these proteins in multiple,
often contradicting biological processes can complicate
their use in the clinic. The cytokine interleukin (IL)-21 is no
exception: while its strength as an anticancer agent has
been established in several animal studies, response rates
in melanoma and renal cell carcinoma patients remain low.
To help guide the design of effective IL-21 therapy, we
have developed a mathematical model that bridges
between the complex biology of IL-21 and its optimal
clinical use. Our model integrates data from preclinical
studies under diverse IL-21 treatment settings, and was
validated by extensive experiments in tumor-bearing mice.
Model simulations predicted that beneficial, clinically
practical IL-21 therapy should be composed of low-dose
schedules, and/or schedules in which several partial doses
are administered rather than a single complete dose.
These findings were subsequently confirmed in mice with
melanoma. Thus, future testing of these strategies in solid
cancer patients can be a promising starting point for
improving IL-21 therapy. Our model can thus provide a
computational platform for rationalizing IL-21 regimens
and streamlining its clinical development.
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introduced directly to the plasma, from which it can be
transported to three secondary tissues (e.g., the liver, kidneys
and bile), reabsorbed to the plasma, degraded, or transferred into
the target tissue. This four compartment IV model was chosen by
analyzing the number of linearity regions in the data reported in
[41] (see details in Text S1, section A). In SC and IP injections, the
model contains continuous drug flow from the administration site,
via up to three compartments, into the plasma site. The absorption
structure was designed to allow: (1) participation of multiple
peripheral compartments in IL-21 transition and decay; (2) non-
sequential transition between compartments, i.e. multi-directional
flow of the drug between tissues. This flexibility was motivated by
our assumption that, similarly to other recombinant cytokines with
complex PK profiles [45], IL-21 can potentially be taken up,
cleared or processed, by several tissues and cells expressing its
receptor. Indeed, the murine biodistribution profile in SC/IP
administrations demonstrated observable multiplex transport of
IL-21 into several peripheral tissues, where its concentrations were
higher than plasma levels during several time points (personal
communication, Dr. P. Thygesen, Novo Nordisk A/S, Denmark).
Of note, similar multi-compartmental active transport was also
described in prior models of IL-21-induced hematological effects
in primates [46,47], in support of this structure.
Non-linear Michaelis-Menten kinetics were initially assumed for
all transition and degradation processes in the model. Such
dynamics have been previously suggested as more suitable for
cytokine models, since they are expected to be better at capturing
complex drug disposition patterns [45]. We also reasoned that
non-linearity would allow higher flexibility of the model and
account for saturation-containing effects. Conversely, an a-priori
linear assumption may cause bias towards underestimation or
overestimation of some PK processes. Of note, non-linear
dynamics also display clear advantages over simpler linear models
in describing certain oncotherapies, and afford substantially
improved goodness-of-fit to PK data [44]. Thus, in our model,
the transition rate of IL-21 from any compartment i to any
compartment j is given by the non-linear term Ji,j:
Ji,j~w
xi{xj

1za xi{xj
 ð1Þ
The latter is a rate-limiting function of the amounts xi and xj,
where parameter w is a constant that always regulates the
reaction rate and a determines the saturation level. The
degradation rate of the drug from any compartment i in the
model is described by term Di, a similar non-linear function of the
amount xi (where d regulates the reaction rate and b determines
the saturation level):
Di~d
xi
1zbxi
ð2Þ
Selected drug transition and degradation events in the resulting
eight ODEs model did in fact necessitate non-linear dynamics, as
implied by values of the saturation PK parameters a and b (Text
S1, Table S1): While the IP route may have been satisfied by a
linear transport description (as evident by small and negligible a
values), SC administration required a combination of linear and
non-linear transport events (as a values were significant). Likewise,
nonlinearity surfaced in some degradation processes under all
administration routes (as shown by large values for b).
Finally, in the absence of sufficient experimental data on the
rate of IL-21 transfer from plasma to the tissue, we assumed a
direct correlation between tissue concentration and plasma
concentrations. Thus, to relate IL-21 concentrations in the plasma
(x0) to those in the target tissue (xT), the two compartments were
correlated by a parameter, s. Drug levels at the tumor site are
therefore a fraction of systemic levels at any given moment:
xT(t)~
x0(t)
s
ð3Þ
Figure 1. Scheme of the systemic IL-21 mathematical model. A model of IL-21 PD effects on immune regulation of tumor growth [39] is
combined with a new IL-21 PK model based on data in mice [41]. Under SC/IP administration, IL-21 is introduced at site (A) and is transported through
3 compartments to the plasma (P). Under IV administration, the drug is injected directly into the plasma. The drug is degraded via 3 additional
compartments. IL-21 concentrations in the target tissue (T) are correlated with the plasma levels by parameter s. In the target site, IL-21 inhibits NK
survival and promotes CTL expansion, while enhancing CPs of both cells and facilitating their tumor cell targeting. Abbreviations: PK-
pharmacokinetics; PD- pharmacodynamics; IV- intravenous; SC- subcutaneous; IP-intraperitoneal; NK- natural killer cell; CTL- cytotoxic T lymphocyte;
CPs- cytotoxic proteins.
doi:10.1371/journal.pcbi.1002206.g001
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an anticancer response by modulating several immune
components [4,5,6,7]. The key in situ processes affected by the
drug were described by our previous six ODEs model, which had
successfully recreated the antitumor effects in mice subject to IL-
21-gene therapy [39,40]. The model comprised the IL-21-
modulated dynamics of the immune effector cells NKs and
CTLs, the intracellular cytotoxic proteins by which these effectors
lyse the tumor cells, IL-21-induced memory ensuring a long-term
CTL response, and the tumor growth (see Text S1, section B).
For the current PD/disease structure (Fig. 1), NK, CTL,
cytotoxic protein, and memory factor populations were described
as in the prior tissue model [39,40]. However, some entities were
altered herein: (1) IL-21 dynamics in the tissue were modified from
the previous system, and set to be correlated with plasma IL-21
levels, effectively binding PK to PD (see above). (2) The new PD
model assumes a CTL-dominance (rather than the prior equal
effector balance) in the IL-21-mediated response (see Parameter
estimation). This is based on the notion that CTLs are likely more
influential than NKs in the scenario of systemic IL-21 treatment
[41]. (3) To describe the baseline growth of both B16 and RenCa,
the disease model here assumes a logistic function. (4) Parameter
values of all prior components were adapted as needed, in order to
comply with the systemic therapy settings, and with the new
RenCa tumor analyzed herein (see Parameter estimation).
Parameter estimation
The model (Fig. 1) was implemented in C (Microsoft Visual
Studio.NET) and MATLAB (The MathWorks, Natick, MA)
programming platforms. The system was solved by fourth-order
Runge Kutta integration. Model parameters were evaluated by a
customized numerical method based on Hooke and Jeeves
optimization [48] combining global and local search heuristics
and least-squares curve-fitting. Parameter sets achieving maximal
model agreement with experimental training data were selected
(see Text S1, Tables S1-S2).
PK parameters. For calibration of the diverse PK models
considered in the multiple-modeling process, serum IL-21
concentrations following a single SC, IP, or IV injection in mice
[41] were used as training datasets. Before calibration, the plasma
volume was set at 2 ml and the injected dose at 50 mg. Each
potential PK model was fit in a process that yielded ten possible
parameter sets. The model was then simulated with these ten sets
under diverse treatment settings: A model was deemed reliable
when its multiple predictions (generated under all sets) were
unified, under all therapeutic scenarios that were simulated. Thus,
the final PK model selected for further simulation (see above, as
also schemed in Fig. S1, and discussed in Text S1, section A)
fulfilled this criterion. For each of the three administration routes
accounted for in this PK model, one representative parameter set
(of the ten sets) is displayed (see Table S1 in Text S1), and the
respective fits are shown as well (Fig. S2A). The best-fitted PK
model (Fig. S1) was selected for further simulation.
Parameter s, relating tissue concentrations of IL-21 to the
plasma concentrations of the drug, was estimated after evaluating
all other PK/PD model parameters. Since tissue biodistribution
data following SC vs. IP injections of IL-21 in unchallenged mice
show different profiles ([41] and personal communication, Dr. P.
Thygesen, Novo Nordisk A/S, Denmark), we allowed s to be
administration-dependent by estimating this parameter separately
for SC and IP. An initial value range for parameter s was obtained
by comparing the drug profile in the blood to the profiles in
various peripheral tissues, which provided a rough estimate of the
ratio of blood:tissue drug concentrations at any given time. This
gave a realistic range of s between 1–100. Exact estimation of s was
accomplished by curve-fitting to training data of B16 dynamics
following IL-21 treatment via an early-initiated (day 3) 50 mg/day
SC/IP regimen [41] (see Fig. 2, ‘‘Model fit’’). Final s values (Text
S1, Table S1) were all within the predetermined biologically
acceptable range.
PD and disease model parameters. Some parameters of
the PD model component were set at their previous values
([39,40], Table S2 in Text S1): Immune system parameters were
set identical for both tumor types, as they reflect indication-
independent processes (i.e. effector cell dynamics, cytotoxicity
effects, and immune memory). Parameters s and D, quantifying
maximal CTL numbers, were taken as tumor-specific since they
represent the immune response intensity and depend on the tumor
immunogenicity [39]; their values for B16 and RenCa were set as
in non-immunogenic and moderately immunogenic tumors,
respectively [39].
Coefficients k1 and k2 (the respective NK and CTL interaction
affinities to the tumor) were re-estimated to reflect a stronger
influence for CTLs in the antitumor response (i.e. k1,k2), as
suggested in these conditions [41]. To evaluate k1 and k2, we used
training data from B16-bearing mice in which these immune cells
were neutralized prior to IL-21 immunotherapy [41]: k1 was
evaluated by curve-fitting to tumor dynamics in T-cell neutralized
mice, thus assuming no CTL activity (i.e. k2=0, Fig. S2B); k2 was
estimated using data from NK-neutralized mice (setting k1=0)
representing a lack of NK activity (Fig. S2B). The obtained k2
Figure 2. Estimation and sensitivity analysis of model param-
eter s. Curve-fits produced during estimation of parameter s, using
experimental training data of B16 dynamics under an early-onset (day 3)
IL-21 treatment (50 mg/day) [41]. The parameter was evaluated per
route of administration (see Table S1 in Text S1), and model-data
approximation is indicated for both SC and IP treatment (‘‘Model fit’’).
Predictions of the model under 2-fold increased or decreased s values
(‘‘Model prediction s62’’ and ‘‘Model prediction s/2’’, respectively)
retrieving these experimental data (Exp), are plotted. Simulations (lines)
are shown with respect to data (circles), given as means6SEM.
doi:10.1371/journal.pcbi.1002206.g002
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Text S1), fulfilling the condition for CTL-dominance over NK.
(Selected simulations were also performed using the original k1 and
k2 values ensuing an equal tumor-killing role, i.e. k1=k2, which is
appropriate in early tumorigenesis; see Text S1, section C).
B16 and RenCa growth parameters (Table S2 in Text S1)
were newly estimated using training data from control (PBS-
treated) mice [41]. Model-evaluated tumor cell numbers were
scaled to volume (mm
3) units, assuming that 10
6 cells equal
1m m
3 [39]. Estimations were carried out by curve-fitting to
data from early treatment conditions where tumors are small at
therapy onset (Fig. S2C), and from late treatments consisting of
large initial tumors (data not shown). Thus, diverse growth
parameter values were obtained for each tumor type and
therapeutic onset.
Model simulation and validation
The model was simulated under numerous IL-21 regimens,
differing in onset, duration, dose, inter-dosing interval, route, etc.
All simulations were repeated several times to ensure output
consistency. Retrospective verification of the model was accom-
plished by checking its prediction accuracy, via statistical
comparison of its output with prior independent validation
datasets (see Experimental data and [41]): Model simulations were
conducted under the specific tumor settings and treatment
conditions of each prior experiment. For prospective model
validation, selected model-identified regimens were tested exper-
imentally, and results were statistically compared to model
predictions at the data sampling times.
Statistical analysis
The goodness-of-fit between the model output and experimental
data was determined by calculating the coefficient of variation
(R
2). To compare between experimental datasets, Student’s t-test
(two-tailed, assuming equal variance) was applied. A P,.05 value
was considered statistically significant.
Results
Sensitivity analysis of model parameters
First, we examined the sensitivity of the model to small
variations in the value of the plasma-tissue correlation factor s,
being that this pivotal parameter simplifies rather complex PK
processes. Simulations of the experimental early-onset IL-21
regimen (50 mg/day applied SC/IP) in the B16-challenged setting
were carried out under diverse s values, in the vicinity of those
obtained through curve-fitting (see Materials and methods and Fig. 2).
After increasing or decreasing s values by two-fold, model
predictions still accurately retrieved the murine data (R
2.0.90;
Fig. 2), and were comparable to the original fits (Fig. 2, ‘‘Model
fit’’). Interestingly, model predictions remained precise even when
modifying the values of the effector-tumor interaction coefficients
k1 and k2 (see Text S1, section C, and also Fig. S3). These results
indicate that model predictions are robust even when s, k1 and k2
values slightly diverge, meaning that different numeric combina-
tions of these parameters, i.e., multiple NK:CTL ratios, can
accomplish the same therapeutic effect. This implies a potentially
wide window of IL-21 doses within which effects may be
comparable.
Retrospective model validation by experiments in IL-21-
treated mice with B16 tumors
Our primary goal was to validate the model’s predictive
accuracy. We therefore compared its output to the experimental
B16 progression following a late (day 8) onset regimen of IL-21,
given at 50 mg/day SC/IP for 3 weeks [41]. All late treatment
simulations were strongly in line with the independent validation
data (R
2.0.90; Fig. 3A), thus verifying the model. Notably, the
model was able to recapitulate the biological behavior even under
the aforementioned modifications in s, k1 and k2 parameter values
(data not shown).
Retrospective model validation by experiments in IL-21-
treated mice with RenCa tumors
Next we assessed the model’s generality by investigating
whether it can predict IL-21 therapy outcomes in other solid
cancer indications, such as RenCa. Tumor growth and selected
immune system parameters were set for RenCa, using training
data in untreated mice and previously calibrated parameter values
for moderately-immunogenic cancers (see Materials and methods and
[39]). Other parameter values were set exactly as in the B16 case.
Simulations of the experimentally-applied IL-21 treatment of
50 mga t3 6/week, given for 3 weeks [41], showed model
predictions to be strongly akin to the observed dynamics under late
(day 12) therapy administered SC, as well as in early (day 7) and
late IP regimens (R
2.0.90; Fig. 3B). Under the early SC regimen,
predicted responses were slightly weaker than observed, yet still
remained within the measurement’s standard deviation (R
2.0.73;
Fig. 3B, upper panel).
To further validate the model for RenCa, we simulated it to
predict the effects another experiment that applied lower IL-21
doses (between 1–20 mg, SC 36/week for 3 weeks). Predictions
were in agreement with the validation set readouts in most doses
(R
2.0.94; Fig. 3C), collectively demonstrating a moderate dose-
dependent decrease in IL-21-mediated tumor eradication. The
10 mg( 3 6/week) simulation experiment gave a good, but slightly
lower, model-data correlation (R
2.0.83; Fig. 3C). The model also
successfully retrieved a retrospective experiment testing a 30 mg
(16/week) IL-21 treatment schedule (R
2.0.90; Fig. 3C).
Improved model-based IL-21 regimens and their
prospective validation in B16-challenged mice
Having validated the model, we used it to gain insights into
better IL-21 therapy in the B16 setting. In particular, we searched
for regimens that would be superior to the standard daily SC
50 mg treatment applied previously [41]. First, we tested whether
the treatment initiation time is a critical factor in determining IL-
21 effects, by simulating different onsets of the standard daily
regimen. The model predicted that earlier therapy initiation
results in stronger anticancer responses, as expected (Fig. 4A). The
simulated tumor mass at the end of therapy (day 20) was lowest
under the earliest regimen, which began one day after B16
challenge: This final tumor load was roughly 15% lower than that
obtained in the standard treatment initiated at day 3. In contrast
to this early regimen, the tumor load resulting from a delayed
regimen, initiated at day 10, was doubled (Fig. 4A). Further
delayed regimens (with onsets as high as day 17) were even less
favorable (data not shown). These results collectively emphasize
the importance of early-onset therapies. Notably, however, not
even the earliest treatment onset was able to fully eradicate the
tumor.
Simulations were performed also to see whether the anticancer
response could be improved by fractionating the IL-21 regimen
into a more intensive high-dosing protocol, as suggested for other
drugs [34,49]. To design alternative schedules, the daily IL-21
regimen (16 SC injections, 50 mg each, given from day 3; [41]) was
taken as a reference point: the same total dose (800 mg) was
Validated Model for Improving IL-21 Immunotherapy
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doses and inter-dosing intervals, creating a collection of regimens
to be tested. Intriguingly, the model predicted that a more
intensive schedule, applying two 25 mg doses per day at a 12-hour
inter-dosing interval, would lead to a 45% lower tumor mass than
that obtained under the standard daily 50 mg regimen (Fig. 4B).
Fractionation into even smaller doses given every few hours
produced slightly lower tumor sizes, yet these responses were not
significantly better than the 25 mg regimen outcomes (Fig. 4B). In
fact, not even the most fractionated schedule could arrive at full
eradication of the tumor. At the other end, less fractionated
regimens comprising large IL-21 doses given every few days had
significantly weaker efficacy (Fig. 4B).
In order to verify our prediction that the fractionated 25 mg/12
hour regimen would be superior to the standard 50 mg/24 hour
schedule, the two were experimentally applied in B16-challenged
mice. Even though both schedules effectively attenuated tumor
progression as compared to control PBS-treated mice (*p,.001;
Fig. 4C), the 25 mg/12 hour regimen was considerably more
successful than the standard 50 mg daily regimen (**p,.05;
Fig 4C), as mathematically predicted. The observed tumor
dynamics under the 25 mg regimen had an excellent fit with the
prior model predictions (R
2.0.90; Fig. 4C), providing strong and
quantitative prospective validation of the model’s precision.
We considered that the fractionated regimen may not be
clinically practical, since it could involve increased costs of
therapy, and, at least in IV delivery, would possibly require
hospitalizing patients. Therefore, the search for better treatment
was limited to simple, widely-acceptable daily administration
schedules. Regimens of one IL-21 dose per day (e.g. 16 SC
injections given between days 3–20 following B16 inoculation)
were simulated under different dose intensities: A dose-dependent
increase in the response, reflected by lowered tumor masses, was
predicted for very low (,5 mg) or very high (.50 mg) levels
(Fig. 5A). Yet interestingly, similar outcomes were predicted for
the 5–50 mg dose range (Fig. 5A). This might be explained by the
conflicting roles of IL-21, enhancing CTL activation while
drastically reducing NK numbers at the same time [39]; It is
likely that in this dosing range, IL-21-increased CTL responses fail
to promote further tumor shrinkage due to the IL-21-inhibition of
NK availability.
A prospective experiment in B16-induced mice examined
whether a low dosing regimen in the plateau range (i.e. 12 mg/
day) could indeed be as effective as the standard 50 mg/day
treatment. Beginning on day 3 following tumor challenge, the two
doses were applied SC, and the tumor mass was measured until day
17. Both the 12 mg and 50 mg doses induced sufficient antitumor
responses in the mice (*p,.05 and **p,.001 compared with PBS-
treated mice; Fig. 5B). Although the 12 mg dose appeared slightly
less potent, its effect was not significantly different from the 50 mg
schedule (ns, p..05; Fig. 5B), as anticipated by the model. Indeed,
the model prediction (Fig. 5A) fit the 12 mg/day outcome to a good
Figure 3. IL-21-induced antitumor effects: model simulations retrospectively verified in experimental murine tumors. Model
predictions (lines) retrieve experimental validation data (circles, triangles) of tumor dynamics from a preclinical study [41], where (A) B16-bearing mice
were treated by a 50 mg/day IL-21 treatment applied SC or IP, starting on day 8 after tumor inoculation; (B) RenCa-challenged mice were treated by
IL-21, 50 mg3 6/week, SC or IP, commencing either early (day 7) or late (day 12) after tumor inoculation; (C) RenCa-bearing mice were SC-
administered various IL-21 doses between 1–20 mg( 3 6/week), or given a 30 mg( 1 6/week) regimen. Data are given as means6SEM.
doi:10.1371/journal.pcbi.1002206.g003
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2=0.89, Fig. 5B). These findings further validate the
model, and are the first indication of an IL-21 dosing range
executing equally potent effects.
Discussion
Immune-targeted therapy is increasingly apparent in the battle
against cancer. Several reagents are in development within this
scope, some already approved for use in certain indications
[1,9,50]. In this study, we have devised and validated a clinically-
relevant mathematical model integrating the PK/PD effects on
immune and disease interactions of IL-21, one of the recent
immunotherapeutic drugs under focus in solid cancers [9].
Following its verification, our model was used for suggesting
beneficial IL-21 treatment policies.
Previous attempts to model cytokine-based immune modulation
of solid malignancies have been mainly theoretical, helping to
elucidate certain characteristics of the tumor-immune system
cross-talk and providing important insights into treatment success
(see for example [23,31,33]). Our former model focused on the
heart of the IL-21 response, retrieving the effects of cytokine gene
therapy to a good extent. Yet, its predictions could not be
extrapolated to the clinical realm. The current work is thus among
the first biomathematical studies accounting for practical treat-
ment aspects of cytokine immunotherapy in general, and IL-21
treatment in particular. Our current model deals with realistic PK
Figure 4. Model-improved IL-21 therapies with modified onset and fractionation. (A) Predicted outcomes (final B16 volumes; squares) of
20-day regimens (50 mg/day given SC) initiated on different days. (B) Predicted outcomes of regimens with the same total IL-21 dose (800 mg/
treatment given SC) yet with different fractionations (i.e. number of injections, inter-dosing intervals and dose intensities). (C) Prospective validation
of the model predictions (lines) in B16-bearing mice treated by a standard (std) 50 mg/day regimen vs. a fractionated (frac) 25 mg/twice daily
schedule, both administered SC between days 3–20 (data in circles). Tumor growth in PBS controls is indicated as well. Means6SEM of data are given
(n=10; *p,0.001 for 25 mg-treated mice vs. PBS-treated mice, and for 50 mg-treated mice vs. PBS-treated mice; **p,0.05 for 25 mg-treated mice vs.
50 mg-treated mice).
doi:10.1371/journal.pcbi.1002206.g004
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ing, patient compliance, etc. Moreover, in contrast to the
customary stand-alone PK/PD modeling approach, we have
integrated IL-21 PK/PD with specific effects on the involved
biological processes, to give a mechanistic, yet minimal, model.
Particularly, our PD/disease model accounts for real entities of the
IL-21 biological processes (effector cells, etc.), which enabled us to
use measurable data and make testable quantitative predictions. At
the same time, we kept our model concise thanks to condensation
of other overly complex biological entities (cytotoxic proteins, etc.)
which are less cardinal and often not measured experimentally.
Overall, our approach provides a robust model that can forecast
the long-term anticancer effects of a specific immunotherapeutic
cytokine, via a clinically-oriented prism.
Our integrated PK/PD model was constructed by an advanced
‘‘multiple-modeling’’ approach, which we found most suitable for
the IL-21 scenario. The selection of a favorable model out of many
analyzed structures and complexities, and the use of non-linear
kinetics, enabled us to explore significantly more functional
possibilities, and allowed for flexibility in the design. Moreover,
rather than forming a model per scenario, we were able to create a
generalized model by describing processes that are mutual to
different therapeutic settings (administration routes, etc.) and
tumor types. This enhanced the robustness of the model, since it
structure was subject to testing under diverse conditions. Indeed,
the model encompasses IL-21-induced outcomes in a wide range
of treatment conditions, under different times and administration
routes. Despite its simplicity, the model accurately predicted IL-
21-relayed effects in B16- and RenCa-challenged mice, both
prospectively and retrospectively. Moreover, the model demon-
strated robust behavior, and predictions were largely insensitive to
modulation of key parameters. With this combined generality and
accuracy, the model can potentially accommodate other clinical
settings and solid cancers where similar immune processes apply
and where IL-21 has been useful (i.e. adenocarcinoma, glioma,
neuroblastoma) [7,8].
A systematic design of clinically applicable IL-21 immunother-
apy strategies has long been called for. Considering the modest
responses of MM and RCC patients to IL-21 therapy
[10,11,12,13,14], it is worthwhile to examine whether the drug
can be more powerful under different treatment approaches.
Previous trial regimens of IL-21 were determined based on the US
Food and Drug Administration guidelines for high-dose IL-2
therapy in MM patients [13], as the two cytokines share homology
and certain effector-inducing functions. Yet, recent findings
demonstrate that IL-2 and IL-21 do not entirely align in their
actions [17,51,52], inferring that the optimal administration
strategies (administration routes, dose intensities, inter-dosing
intervals, etc.) likely vary between the two agents. Local IL-21
delivery or expression have been proposed, by us and others, to be
potentially effective and safe approaches [17,39,53], yet such
therapeutic methods are not yet available for clinical use. Our
systemic model analysis therefore represents a new effort to
identify improved, clinically-appropriate IL-21 therapies, using the
preclinical tumor models B16 and RenCa as case studies.
Simulations of differently dosed IL-21 schedules gave rise to
central new insights. According to the model, comparable
antitumor responses are induced by daily IL-21 doses within the
5–50 mg range. This was prospectively confirmed in B16-
challenged mice, in which a substantially lower IL-21 dose
(roughly 12 mg/day) was as effective as the standard 50 mg/day
treatment. An insensitive range of IL-21 doses with similar efficacy
is not unreasonable, considering that the drug respectively inhibits
or induces NKs and CTLs, two cells which complement one
another in the process of cancer targeting. This model-aided
identification of smaller doses with similar therapeutic efficacy
could have immense clinical value, possibly reducing putative IL-
21-associated toxicities. Adverse events have indeed been reported
in IL-21-treated patients [10,11,12,13,14]. IL-2 and interferon-a,
other cytokine drugs, are associated with severe hematological and
neuropsychiatric side effects complicating their use [2]. Recent
PK/PD models of toxic IL-21 effects on body temperature and red
blood cell regulation [46,47] present a possible framework in
which our improved regimens can be confirmed for clinical safety.
Another interesting concept surfacing from our simulations
addresses IL-21 fractionation. The model predicted improved
antitumor responses by simple partitioning of the experimental
regimen (a single 50 mg dose/day) into an equally intense regimen
of 25 mg doses given twice daily. This was prospectively validated
by experiments in which the fractionation-treated mice ended
therapy with ca. half of the tumor load observed after the standard
treatment. Model-predicted halving of a daily dose was sufficient
to significantly enhance IL-21 efficacy, and further division of the
doses was not imperative. Indeed, fractionation of cancer
therapeutics was recommended in the past by mathematical
modeling [29], and its beneficial effects have been validated
Figure 5. Model-improved alternative-dosing IL-21 regimens.
(A) Predicted outcomes (final B16 volumes) of various 20-day
treatments (initialized at day 3, and given SC), where different daily
dose are applied (squares). (B) Experimental B16 dynamics following
prospective treatments under the standard (std) 50 mg/day regimen, or
under a model-based reduced-dosing (low) schedule (12 mg/day). Data
(circles) are shown vs. model simulations (lines). Tumor growth in PBS
controls appears as well. Means6SEM of data are indicated (n=10;
*p,0.05 for 12 mg-treated mice vs. PBS-treated mice; **p,0.001 for
50 mg-treated mice vs. PBS-treated mice; ns-not significant for 12 mg-
treated mice vs. 50 mg -treated mice).
doi:10.1371/journal.pcbi.1002206.g005
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strategy has mostly been applied in the context of radiation
therapy and chemotherapy [54], yet our results, which clearly
indicate the benefit of fractionated IL-21 dosing, propose its
relevance also to immune-modulating drugs. Notwithstanding,
fractionation may be impractical, reducing patient compliance and
requiring hospitalization in certain cases. Moreover, embarking on
new clinical studies to test fractionation therapy is a large and
expensive task, and further adjustment of the mathematical model
to humans is needed before engaging in such endeavors. Our
findings also raise the question whether IL-21 ought to be
administered by available ‘‘slow and continuous release’’ drug
delivery methods, which can be viewed as regimens of maximal
partitioning. Past cytokine-gene therapy experiments in mice
showed complete eradication of IL-21-secreting tumors in which
the drug was released in low continuous levels directly in the target
tissue [7,9], supporting the possible advantage of fractionated
regimens. Future implementation of such routes of drug delivery
within our model can allow to specifically analyze the benefit of
such strategies for IL-21 therapy.
Our present results set the stage for constructing a humanized
IL-21 model, to serve as a tool for streamlining development of the
drug, and in the future, hopefully, also for personalizing cytokine
immunotherapy. The model, up-scaled to the clinical arena, can
entertain diverse cancer indications, patient-specific characteris-
tics, and different modes of therapy. Newly-discovered IL-21
properties of relevance to the anticancer response, such as
modulation of T regulatory cell functions [17] and anti-angiogenic
properties [18], may be introduced in the evolving IL-21 model.
Finally, considering the growing interest in combination therapies
for solid cancers, and the promising preclinical and clinical
responses observed when applying IL-21 with monoclonal
antibodies or signaling inhibitors [9,50], a future model will also
study IL-21 therapy in combination with additional therapeutic
reagents.
Supporting Information
Figure S1 Scheme of the IL-21 PK model. The PK model
consists of 4 compartments for IV administration, or of 8
compartments for SC/IP drug application. IL-21 dynamics in
each compartment (denoted by x) are mathematically detailed in
Section A. Parameters k regulate drug transfer rates, and
parameters d control drug degradation rates.
(TIF)
Figure S2 Model curve-fitting for evaluation of selected
parameters. Parameters newly introduced in the systemic PK/
PD model were estimated by curve-fitting, according to the data in
[1]. (A) Final model fits following the calibration of PK
parameters, which utilized data from normal healthy mice that
were IL-21 administered (50 mg) via IV, SC, and IP routes. (B) Fits
obtained in the evaluation of NK and CTL affinity parameters, by
data from diseased IL-21-treated mice in which CTLs and NKs
were neutralized (respectively). (C) Fits obtained in the evaluation
of B16 and RenCa growth parameters, via data from diseased
untreated (control) mice. Means6SEM of data are indicated.
(TIF)
Figure S3 Sensitivity analysis of effector-tumor inter-
action parameters. Retrieval of experimental training data of
B16 dynamics under early IL-21 treatment (50 mg/day), by the
model, assuming either a ‘‘CTL-dominating’’ response (k1,k2; see
parameter estimation in Materials and methods), or an ‘‘equal NK/
CTL balance’’ response (k1=k2) inspired by the previous gene-
therapy model [2,3]. Simulations (lines) are shown with respect to
data (circles), given as means6SEM.
(TIF)
Text S1 Detailed description of PK model equations
(section A), PD and disease model equations (section B),
analysis of parameter sensitivity (section C), and
parameter values for the full PK/PD/disease model
(Tables S1-S2).
(DOC)
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